Record mula sa primary source
Decision-gradeTopline na resulta
Kodiak DAYBREAK Phase 3 topline para sa Zenkuda at KSI-501 inaasahan noong Setyembre 2026
Kinukumpirma ng 8-K na ang DAYBREAK Phase 3 study ng Zenkuda at KSI-501 sa treatment-naïve wet AMD ay nasa tamang iskedyul para sa one-year primary endpoint topline data sa Setyembre 2026. Kumpleto na ang enrollment at patuloy ang kumpanya sa mga aktibidad na paghahanda ng BLA para sa Zenkuda. Ang pangalawang Phase 3 readout para sa KSI-101 sa MESI ay inaasahan din sa Disyembre 2026.
Mahahalagang fact
- Na-file
- Ago 13, 2026, 08:00 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Neutral
- Kumpanya
KODKodiak Sciences- Asset
- Zenkuda
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- DRSS 2-hakbang
- 62.5% kumpara sa 3.3% (p<0.0001)
- Pagbawas ng panganib ng STC
- 85% (2.4% kumpara sa 15.8%, p=0.0001)
Sipi mula sa source
EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We remain on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by December 2026 PEAK Phase 3 Pivotal Analysis 1 topline results evaluating KSI-101 in Macular